U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
LODOCO® (colchicine, 0.5 mg tablets) Reduces Cardiac Event Risk in Adult Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) by an Additional 31% as Compared to Placebo.* LODOCO May Target Residual Inflammation as an Underlying Cause of ASCVD and May be Used Alone or in Combination with Cholesterol-Lowering Medications Parsippany, NJ – June 20, 2023 – AGEPHA […]